You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,260,097


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,260,097
Title:Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.
Inventor(s): Harkin; Denis Paul (Dromore, GB), Patterson; Fionnuala (Greenisland, GB), Trinder; Claire (Stratford-upon-Avon, GB), O\'Brien; Eamonn J. (Hillsborough, GB), Michie; Caroline (Nr Kirkcaldy, GB), Gourley; Charlie (Dumfermline, GB), Hill; Laura A. (Lisburn, GB), Keating; Katherine E. (Magherafelt, GB), O\'Donnell; Jude (Galbally, GB), Bylesjo; Max (Glasgow, GB), Deharo; Steve (Hillsborough, GB), Proutski; Vitali (Oxford, GB), Kennedy; Richard (Belfast, GB), Davison; Timothy (Hillsborough, GB), Winter; Andreas (Gersthofen, DE), McCavigan; Andrena (Derryadd Lurgan, IE)
Assignee: Almac Diagnostics Limited (Craigavon, GB)
Application Number:14/123,406
Patent Claims:1. A method of treating a subgroup of subjects from a population of subjects having ovarian cancer, prostate cancer, glioblastoma, or breast cancer comprising: (i) providing a subject from the population of subjects known to overexpress at least one gene relative to a pre-defined cut-off threshold value which separates a particular disease into a first phenotype that indicates responsiveness to an anti-angiogenic agent and a second phenotype that indicates resistance to the anti-angiogenic agent, wherein the at least one gene is selected from the group consisting of GJB2, MMP13, GFPT2, BICC1, CDH11, MRVI1, PMP22, COL11Al, IGFL2, LUM, NTM, BGN, COL3A1, COL10A1, RAB31, ANGPTL2, PLAU, COL8A1, MIR1245, POLD2, NKD2, FZD1, COPZ2, ITGA5, VGLL3, MMP14, VCAN, THBS2, RUNX2, TIMP3, SFRP2, COL1A2, COL5A2, SERPINF1, KIF26B, TNFAIP6, MMP2, FN1, ALPK2, CTSK, LOXL1, and FAP in a tumor sample from the subject; and (ii) administering the anti-angiogenic agent to the subject in an amount sufficient to inhibit angiogenesis in the cancer.

2. The method of claim 1, wherein the method measures the level of mRNA, cRNA, cDNA, or protein of the at least one gene.

3. The method of claim 1, wherein the cancer is ovarian cancer.

4. The method of claim 3, wherein the method measures the level of mRNA, cRNA, cDNA, or protein of the one gene.

5. The method of claim 1, wherein the anti-angiogenic agent is selected from VEGF pathway-targeted therapeutic agents, angiopoietin-TIE2 pathway inhibitors, endogenous angiogenic inhibitors, and immunomodulatory agents.

6. The method of claim 5, wherein the VEGF pathway-targeted therapeutic agent(s) is chosen from bevacizumab (Avastin), afibercept (VEGF Trap), IMC-1121B (Ramucirumab), imatinib (Gleevec), sorafenib (Nexavar), gefitinib (Iressa), sunitinib (Sutent), erlotinib, tivozinib, cediranib (Recentin), pazopanib (Votrient), BIBF 1120 (Vargatef), dovitinib, semaxanib (Sugen), axitinib (AG013736), vandetanib (Zactima), nilotinib (Tasigna), dasatinib (Sprycel), vatalanib, motesanib, ABT-869, TKI-258, and a combination thereof.

7. The method of claim 6, wherein the VEGF pathway-targeted therapeutic agent is bevacizumab.

8. The method of claim 1, wherein the cancer is prostate cancer.

9. The method of claim 1, wherein the cancer is glioblastoma.

10. The method of claim 1, wherein the cancer is breast cancer.

11. A method of treating ovarian cancer, prostate cancer, glioblastoma, or breast cancer in a patient comprising administering an anti-angiogenic agent to the patient in an amount sufficient to inhibit angiogenesis in the cancer, wherein the patient is known to overexpress at least one gene relative to a pre-defined cut-off threshold value which separates a particular disease into a first phenotype that indicates responsiveness to the anti-angiogenic agent and a second phenotype that indicates resistance to the anti-angiogenic agent, wherein the at least one gene is selected from the group consisting of GJB2, MMP13, GFPT2, BICC1, CDH11, MRVI1, PMP22, COL11Al, IGFL2, LUM, NTM, BGN, COL3A1, COL10A1, RAB31, ANGPTL2, PLAU, COL8A1, MIR1245, POLD2, NKD2, FZD1, COPZ2, ITGA5, VGLL3, MMP14, VCAN, THBS2, RUNX2, TIMP3, SFRP2, COL1A2, COL5A2, SERPINF1, KIF26B, TNFAIP6, MMP2, FN1, ALPK2, CTSK, LOXL1, and FAP in a sample of the cancer.

12. The method of claim 11, wherein the cancer is ovarian cancer.

13. The method of claim 12, wherein the method measures the level of mRNA, cRNA, cDNA, or protein of the one gene.

14. The method of claim 11, wherein the method measures the level of mRNA, cRNA, cDNA, or protein of the at least one gene.

15. The method of claim 11, wherein the anti-angiogenic agent is selected from VEGF pathway-targeted therapeutic agents, angiopoietin-TIE2 pathway inhibitors, endogenous angiogenic inhibitors, and immunomodulatory agents.

16. The method of claim 15, wherein the VEGF pathway-targeted therapeutic agent(s) is chosen from bevacizumab (Avastin), afibercept (VEGF Trap), IMC-1121B (Ramucirumab), imatinib (Gleevec), sorafenib (Nexavar), gefitinib (Iressa), sunitinib (Sutent), erlotinib, tivozinib, cediranib (Recentin), pazopanib (Votrient), BIBF 1120 (Vargatef), dovitinib, semaxanib (Sugen), axitinib (AG013736), vandetanib (Zactima), nilotinib (Tasigna), dasatinib (Sprycel), vatalanib, motesanib, ABT-869, TKI-258, and a combination thereof.

17. The method of claim 16, wherein the VEGF pathway-targeted therapeutic agent is bevacizumab.

18. The method of claim 11, wherein the patient is a human.

19. The method of claim 11, wherein the cancer is prostate cancer.

20. The method of claim 11, wherein the cancer is glioblastoma.

21. The method of claim 11, wherein the cancer is breast cancer.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.